197 related articles for article (PubMed ID: 34110090)
1. Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia.
Word TA; Quick AP; Miyake CY; Shak MK; Pan X; Kim JJ; Allen HD; Sibrian-Vazquez M; Strongin RM; Landstrom AP; Wehrens XHT
J Cell Mol Med; 2021 Jun; 25(13):6115-24. PubMed ID: 34110090
[TBL] [Abstract][Full Text] [Related]
2. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
[TBL] [Abstract][Full Text] [Related]
3. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
[TBL] [Abstract][Full Text] [Related]
4. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
[TBL] [Abstract][Full Text] [Related]
5. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
6. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
7. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
8. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
[TBL] [Abstract][Full Text] [Related]
9. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
10. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential.
Stutzman MJ; Kim CSJ; Tester DJ; Hamrick SK; Dotzler SM; Giudicessi JR; Miotto MC; Gc JB; Frank J; Marks AR; Ackerman MJ
Stem Cell Reports; 2022 Sep; 17(9):2023-2036. PubMed ID: 35931078
[TBL] [Abstract][Full Text] [Related]
11. Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia.
Ben Jehuda R; Barad L
J Atr Fibrillation; 2016; 9(2):1423. PubMed ID: 27909533
[TBL] [Abstract][Full Text] [Related]
12. Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes.
Novak A; Lorber A; Itskovitz-Eldor J; Binah O
Rambam Maimonides Med J; 2012 Jul; 3(3):e0015. PubMed ID: 23908839
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients.
Pölönen RP; Penttinen K; Swan H; Aalto-Setälä K
Stem Cells Int; 2018; 2018():9109503. PubMed ID: 29760739
[TBL] [Abstract][Full Text] [Related]
14. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K
PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245
[TBL] [Abstract][Full Text] [Related]
16. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
[TBL] [Abstract][Full Text] [Related]
17. Post-Translational Modifications and Diastolic Calcium Leak Associated to the Novel RyR2-D3638A Mutation Lead to CPVT in Patient-Specific hiPSC-Derived Cardiomyocytes.
Acimovic I; Refaat MM; Moreau A; Salykin A; Reiken S; Sleiman Y; Souidi M; Přibyl J; Kajava AV; Richard S; Lu JT; Chevalier P; Skládal P; Dvořak P; Rotrekl V; Marks AR; Scheinman MM; Lacampagne A; Meli AC
J Clin Med; 2018 Nov; 7(11):. PubMed ID: 30413023
[TBL] [Abstract][Full Text] [Related]
18. Modeling polymorphic ventricular tachycardia at rest using patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Sleiman Y; Souidi M; Kumar R; Yang E; Jaffré F; Zhou T; Bernardin A; Reiken S; Cazorla O; Kajava AV; Moreau A; Pasquié JL; Marks AR; Lerman BB; Chen S; Cheung JW; Evans T; Lacampagne A; Meli AC
EBioMedicine; 2020 Oct; 60():103024. PubMed ID: 32980690
[TBL] [Abstract][Full Text] [Related]
19. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
[TBL] [Abstract][Full Text] [Related]
20. Generation of two induced pluripotent stem cell lines from catecholaminergic polymorphic ventricular tachycardia patients carrying RYR2 mutations.
Kong X; Belbachir N; Zeng W; Yan CD; Navada S; Perez MV; Wu JC
Stem Cell Res; 2023 Jun; 69():103111. PubMed ID: 37210947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
